Table 3 Effects of high-dose and low-dose GCs on the treatment of AMAN
Parameters | High-dose (n=35) | Low-dose (n=27) | P value (two-tailed) |
|---|---|---|---|
Age (years) | 49.31±15.69 | 47.70±19.80 | 0.722 |
Male, n (%) | 20(51.4) | 14(51.9) | 0.798 |
Rural area, n (%) | 26 (74.3) | 17(63.0) | 0.805 |
Hughes score on admission (g) | 3.11±0.93 | 3.07±0.83 | 0.940 |
Hughes score at nadir (mean, g) | 3.63±0.69 | 3.81±0.68 | 0.262 |
Neurological symptoms, n (%) | |||
Facial/bulbar paralysis | 4(11.4) | 6(22.2) | 0.308 |
Oculomotor paralysis | 2(5.7) | 1(3.7) | 1.000 |
Paresthesia | 12(34.3) | 8(29.6) | 0.788 |
Hyperreflexia | 7(20.0) | 5(18.5) | 1.000 |
Complication, n (%) | |||
Autonomic dysfunction | |||
Hypertension | 6(17.1) | 5(18.5) | 0.735 |
Cardiac arrhythmia | 4(11.4) | 3(11.1) | 1.000 |
Urinary retention | 5(14.3) | 7(25.9) | 0.335 |
Deep venous thrombosis | 1(2.9) | 2(7.4) | 0.575 |
Dyspnoea | 4(11.4) | 6(22.2) | 0.308 |
Pulmonary infection | 3(8.6) | 5(18.5) | 0.279 |
Diabetes | 3(8.6) | 1(3.7) | 0.626 |
Laboratory abnormality, n (%) | |||
Hyponatraemia | 6(17.1) | 7(25.9) | 0.532 |
Hypoalbuminaemia | 9(25.7) | 5(18.5) | 0.555 |
Hospital stay (days) | 15.66±8.11 | 14.96±6.20 | 0.943 |
Mechanical ventilation, n (%) | 3(8.6) | 4(14.9) | 0.689 |
Death in hospital stay, n (%) | 0 | 1(5.00) | - |
Hughes score at discharge (g) | 2.80±0.76 | 2.89±0.70 | 0.591 |
Hughes score of 3 months after onset (g) | 2.43±0.74 | 2.59±0.89 | 0.386 |